Roivant Sciences (NASDAQ:ROIV) CEO Sells $4,170,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $20.85, for a total value of $4,170,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,497,908 shares of the company’s stock, valued at approximately $31,231,381.80. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.22, for a total transaction of $4,044,000.00.
• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The stock was sold at an average price of $17.06, for a total transaction of $2,020,211.08.
• On Wednesday, October 15th, Eric Venker sold 414,683 shares of Roivant Sciences stock. The stock was sold at an average price of $16.93, for a total transaction of $7,020,583.19.
• On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The shares were sold at an average price of $17.05, for a total transaction of $5,426,708.10.
• On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The stock was sold at an average price of $16.25, for a total transaction of $336,813.75.
• On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The stock was sold at an average price of $16.30, for a total value of $1,710,522.00.
• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The shares were sold at an average price of $16.20, for a total value of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The stock was sold at an average price of $16.34, for a total value of $2,800,610.64.
• On Tuesday, October 7th, Eric Venker sold 355,161 shares of Roivant Sciences stock. The shares were sold at an average price of $16.15, for a total value of $5,735,850.15.
• On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The stock was sold at an average price of $14.83, for a total value of $9,061,130.00.

Roivant Sciences Stock Up 3.6%

NASDAQ ROIV opened at $22.10 on Friday. The business’s fifty day simple moving average is $19.38 and its 200-day simple moving average is $14.70. The firm has a market cap of $15.37 billion, a PE ratio of -39.46 and a beta of 1.22. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $22.45.

Institutional Trading of Roivant Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amundi increased its holdings in Roivant Sciences by 18.1% in the first quarter. Amundi now owns 398,729 shares of the company’s stock valued at $3,991,000 after buying an additional 61,214 shares during the last quarter. Inspire Investing LLC purchased a new stake in Roivant Sciences during the 1st quarter worth about $303,000. IFG Advisory LLC acquired a new position in shares of Roivant Sciences during the 2nd quarter worth about $255,000. Franklin Resources Inc. purchased a new position in shares of Roivant Sciences in the 2nd quarter valued at about $997,000. Finally, Peak Financial Advisors LLC acquired a new stake in shares of Roivant Sciences during the 2nd quarter worth about $472,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Jefferies Financial Group boosted their target price on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Guggenheim reaffirmed a “buy” rating and set a $25.00 price target on shares of Roivant Sciences in a research report on Friday, November 14th. Leerink Partners reiterated an “outperform” rating and issued a $29.00 price objective on shares of Roivant Sciences in a report on Tuesday, November 11th. Weiss Ratings raised Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. Finally, Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.31.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.